# US 2023/0416372 A1 · IMMUNOSILENCING Fc VARIANTS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0416372 A1
- Document ID: US20230416372A1
- Status: Published application
- Kind: A1
- Application number: 18/457,687
- Filed: 2023-08-29
- Published: 2023-12-28
- Earliest claimed: 2021-11-02
- Assignees: Visterra, Inc.
- Applicants: Visterra, Inc.
- Inventors: Karthik Viswanathan; Lauren Olinski; Ramki Ramakrishnan; Aditi Deshpande; Gregory Babcock; Zachary Shriver
- Web page: https://patentgrep.com/patent/US20230416372A1

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides, among other things Fc variants that have significantly reduced ADCC, ADCP and CDC function As described herein, the present disclosure is, in part based on identification of novel combinations of mutations that abolish binding to all FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, FcγRIIb, and C1q.

## Claims

### Claim at position 1

1-39. (canceled)

### Claim 40

An antibody comprising an Fc variant of a wild-type human IgG4 Fc region, said Fc variant comprising amino acid substitutions of S228P, F234V, L235E, and D265G, wherein the residues are numbered according to the EU index.

### Claim 41 (depends on 40)

The antibody of claim 40, wherein the antibody is a monospecific antibody.

### Claim 42 (depends on 40)

The antibody of claim 40, wherein the antibody is a bispecific antibody.

### Claim 43 (depends on 40)

The antibody of claim 40, wherein the antibody is a multispecific antibody.

### Claim 44

An antibody comprising an Fc variant of a wild-type human IgG1 Fc region, said Fc variant comprising amino acid substitutions of L234F, L235E, D265G, A330S, and P331S, wherein the residues are numbered according to the EU index.

### Claim 45 (depends on 44)

The antibody of claim 44, wherein the antibody is a monospecific antibody.

### Claim 46 (depends on 44)

The antibody of claim 44, wherein the antibody is a bispecific antibody.

### Claim 47 (depends on 44)

The antibody of claim 44, wherein the antibody is a multispecific antibody.
